IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: A high percentage of grade II and III gliomas have mutations in the gene encoding isocitrate dehydrogenase (IDH1). This mutation is always a heterozygous point mutation that affects the amino acid arginine at position 132 and results in loss of its native enzymatic activity and gain of alternative enzymatic activity (producing D‐2‐hydroxyglutarate). The objective of this study was to investigate the cellular effects of R132H mutations in IDH1. Methods: Functional consequences of IDH1 R132H mutations were examined among others using fluorescence‐activated cell sorting, kinome and expression arrays, biochemical assays, and intracranial injections on 3 different (glioma) cell lines with stable overexpression of IDH1 R132H. Results: IDH1 R132H overexpression in established glioma cell lines in vitro resulted in a marked decrease in proliferation, decreased Akt phosphorylation, altered morphology, and a more contact‐dependent cell migration. The reduced proliferation is related to accumulation of D‐2‐hydroxyglutarate that is produced by IDH1 R132H. Mice injected with IDH1 R132H U87 cells have prolonged survival compared to mice injected with IDH1 wt or green fluorescent protein–expressing U87 cells. Interpretation: Our results demonstrate that IDH1 R132H dominantly reduces aggressiveness of established glioma cell lines in vitro and in vivo. In addition, the IDH1 R132H‐IDH1 wt heterodimer has higher enzymatic activity than the IDH1 R132H‐IDH1 R132H homodimer. Our observations in model systems of glioma might lead to a better understanding of the biology of IDH1 mutant gliomas, which are typically low grade and often slow growing. Ann Neurol 2011;69:455–463
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“The IDH1 mutation frequency is inversely correlated to tumor grade,(3,4) with the lowest frequency observed in glioblastoma multiformes.(5) IDH1 mutations are always heterozygous missense mutations affecting the arginine at position 132.”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“These data are in line with the recently suggested hypothesis that IDH1 induces promoter methylation.(38) However, not all IDH1 mutated tumors are CIMP positive, nor is the effector gene TET2 differentially expressed between IDH1-expressing and IDH1-expressing U87 and U138 cells.”
ResultRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 1×
“The only other tumor type in which regular IDH1 and IDH2 mutations are detected is acute myeloid leukemia (AML).(16) IDH1 catalyses the oxidative decarboxylation of isocitrate into a-ketoglutarate (aKG), thereby using nicotinamide adenine dinucleotide phosphate (NADP) as an electron acceptor.”
BackgroundWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 2×
“The mutated IDH1 enzyme (R132H, IDH1) shows a strongly decreased enzymatic activity toward isocitrate, leading to lower aKG production, thereby increasing hypoxia inducible factor 1a levels.(15,18,19) In addition, IDH1 has an altered enzymatic activity and uses aKG as a substrate to produce D-2-hydroxyglutarate (D-2HG…”
BackgroundAnalysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 1×
“IDH1 mutations are an early event in tumorigenesis; they arise even before TP53 mutations or loss of 1p and 19q.(7) Patients with IDH1 mutations are generally younger, and mutations are associated with prolonged survival.”
BackgroundGross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736 · cited 1×
“Others have studied and reported on IDH1 mutated enzymes from cell lysates that also contain endogenous IDH1(22) or have not tested the enzymatic activity toward aKG of the combination of IDH1 mutant and wild-type enzyme.(19,21) The increased alternative enzyme activity could be explained by the fact that IDH1 functio…”
BackgroundCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2010) · Nature · doi:10.1038/nature09132 · Cited by 613 · cited 1×
“Our results appear contradictory, with a presumed oncogenic role of IDH1 and D-2-HG as an oncometabolite.(20,22,34) However, our results may be explained if”
ResultIsocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222 · cited 2×
“Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) are very common in all grade II and III gliomas, often occurring at frequencies >70%.(1,2) The IDH1 mutation frequency is inversely correlated to tumor grade,(3,4) with the lowest frequency observed in glioblastoma multiformes.”
BackgroundSelf-citationIDH2 Mutations in Patients with d -2-Hydroxyglutaric Aciduria
Kranendijk, M., Struys, E. A., van Schaftingen, E., Gibson, K. M., Kanhai, W. A., van der Knaap, M. S., Amiel, J., Buist, N. R., Das, A. M., de Klerk, J. B., et al. (2010) · Science · doi:10.1126/science.1192632 · Cited by 195 · cited 1×
“It has been reported that the IDH1 and IDH2 mutation spectra differ across the various diseases (glioma, AML and D-2HG aciduria).(6,13,36,37) It is tempting to speculate that these oncogenic properties vary across the different IDH1 and IDH2 mutations.”
BackgroundSelf-citation
Cited by
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., Deng, X., Wang, Y., Weng, X., Hu, C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.031 · Cited by 1,137
“Recent studies further showed that IDH mutations and R-2HG exhibit growth-suppressive activity and glycolysis-inhibitory function 90 Cell 172, 90–105, January 11, 2018 ª 2017 Elsevier Inc. (legend on next page) Cell 172, 90–105, January 11, 2018 91 in gliomas (Bralten et al., 2011; Fu et al., 2015).”
BackgroundIDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K.-L., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 458
Calvert, A. E., Chalastanis, A., Wu, Y., Hurley, L. A., Kouri, F. M., Bi, Y., Kachman, M., May, J. L., Bartom, E., Hua, Y., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.014 · Cited by 204
“Expression of R132H IDH1 in established IDH1 wildtype glioma cell lines reduced proliferation in vitro and extended the survival of mice bearing derived orthotopic xenografts (Bralten et al., 2011).”
Background
Metadata
- Authors
- Bralten, L. B. C., Kloosterhof, N. K., Balvers, R., Sacchetti, A., Lapre, L., Lamfers, M., Leenstra, S., de Jonge, H., Kros, J. M., Jansen, E. E. W., Struys, E. A., Jakobs, C., Salomons, G. S., Diks, S. H., Peppelenbosch, M., Kremer, A., Hoogenraad, C. C., Sillevis Smitt, P. A. E., & French, P. J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-03
- Volume
- 69
- Issue
- 3
- Pages
- 455-463
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2149363397
- Cited by
- 141
- References
- 13
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.